Prevalence and prognostic associations of cardiac abnormalities among hospitalized patients with COVID-19: a systematic review and meta-analysis.
Prevalence and prognostic associations of cardiac abnormalities among hospitalized patients with COVID-19: a systematic review and meta-analysis.
复制标题
DOI：
10.1038/s41598-021-87961-x
复制
发表时间：
2021-04-19
影响因子：
4.6
通讯作者：
Dans LF
中科院分区：
文献类型：
--
作者：
Dy LF;Lintao RCV;Cordero CP;Cabaluna ITG;Dans LF
虽然大多数患者可以通过新冠肺炎康复，但它与心脏、肺部和神经系统的并发症有关。尽管没有正式的诊断标准，但通过生物标志物和成像技术，已经在几项研究中观察到了新冠肺炎相关性心肌病。本研究旨在估计新冠肺炎患者心脏异常的比例，并确定新冠肺炎患者心脏异常与疾病严重程度和死亡率的关系。从电子数据库(PubMed、Embase、Cochrane Library、CNKI)和预印服务器(MedRxiv、BioRxiv、Chinaxiv)获取了2019年12月1日至2020年9月30日发表的观察性研究。有患病率数据的研究被包括在合并患病率的计算中，而与对照组的研究被包括在优势比的计算中。如果在同一项研究中进行了多项测试，得出了不同的流行率值，则使用最大的一项作为该特定研究的流行率的衡量标准。Metafor使用R软件包版本4.0.2进行Metafor分析。通过数据库检索共检索到400条记录，最终纳入24篇文章。在20项研究中，心脏异常的合并患病率被计算为0.31[95%可信区间(CI)为(0.23；0.41)]，具有统计学意义的异质性(变异百分比或I平方统计量I2 = 97%，p <； 0.01)。19项研究的合并分析显示，心脏异常与疾病严重程度和死亡率相关的总体优势比(OR)为6.87[95%-CI(3.92；12.05)]，具有统计学上显著的异质性(I2 = 85%，研究间方差或t平方统计量τ2 = 1.1485，p <； 0.01)。由于心脏异常的合并患病率具有很高的不确定性，以及新冠肺炎患者严重程度或死亡率的风险(尽管风险增加是肯定的)无法量化，因此需要更多的长期预后研究来检查新冠肺炎的长期并发症，并正式确定“新冠肺炎相关性心肌病”的明确标准。
Although most patients recover from COVID-19, it has been linked to cardiac, pulmonary, and neurologic complications. Despite not having formal criteria for its diagnosis, COVID-19 associated cardiomyopathy has been observed in several studies through biomarkers and imaging. This study aims to estimate the proportion of COVID-19 patients with cardiac abnormalities and to determine the association between the cardiac abnormalities in COVID-19 patients and disease severity and mortality. Observational studies published from December 1, 2019 to September 30, 2020 were obtained from electronic databases (PubMed, Embase, Cochrane Library, CNKI) and preprint servers (medRxiv, bioRxiv, ChinaXiv). Studies that have data on prevalence were included in the calculation of the pooled prevalence, while studies with comparison group were included in the calculation of the odds ratio. If multiple tests were done in the same study yielding different prevalence values, the largest one was used as the measure of prevalence of that particular study. Metafor using R software package version 4.0.2 was used for the meta-analysis. A total of 400 records were retrieved from database search, with 24 articles included in the final analysis. Pooled prevalence of cardiac abnormalities in 20 studies was calculated to be 0.31 [95% Confidence Intervals (CI) of (0.23; 0.41)], with statistically significant heterogeneity (percentage of variation or I-squared statistic I2 = 97%, p < 0.01). Pooled analysis of 19 studies showed an overall odds ratio (OR) of 6.87 [95%-CI (3.92; 12.05)] for cardiac abnormalities associated with disease severity and mortality, with statistically significant heterogeneity (I2 = 85%, between-study variance or tau-squared statistic τ2 = 1.1485, p < 0.01). Due to the high uncertainty in the pooled prevalence of cardiac abnormalities and the unquantifiable magnitude of risk (although an increased risk is certain) for severity or mortality among COVID-19 patients, much more long-term prognostic studies are needed to check for the long-term complications of COVID-19 and formalize definitive criteria of “COVID-19 associated cardiomyopathy”.
登录
查看更多内容
影响因子：
7.9
作者：
Taleb NN;Bar-Yam Y;Cirillo P
通讯作者：
Cirillo P
影响因子：
19.6
作者：
Cirillo, Pasquale;Taleb, Nassim Nicholas
通讯作者：
Taleb, Nassim Nicholas
影响因子：
1.8
作者：
Agresti, A;Coull, BA
通讯作者：
Coull, BA
影响因子：
24
作者：
Puntmann, Valentina O.;Carerj, M. Ludovica;Nagel, Eike
通讯作者：
Nagel, Eike
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N